pyrimidinones and Port-Wine-Stain

pyrimidinones has been researched along with Port-Wine-Stain* in 1 studies

Other Studies

1 other study(ies) available for pyrimidinones and Port-Wine-Stain

Article	Year
Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise. Pediatric dermatology, 2022, Volume: 39, Issue:2 Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16-year-old woman with CM-AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen-activated protein kinase (MEK) inhibitor. Topics: Adolescent; Arteriovenous Malformations; Capillaries; Female; Humans; p120 GTPase Activating Protein; Port-Wine Stain; Pyridones; Pyrimidinones	2022

Article

Year

Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise.

Pediatric dermatology, 2022, Volume: 39, Issue:2

Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16-year-old woman with CM-AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen-activated protein kinase (MEK) inhibitor.

Topics: Adolescent; Arteriovenous Malformations; Capillaries; Female; Humans; p120 GTPase Activating Protein; Port-Wine Stain; Pyridones; Pyrimidinones

2022